A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of combined chemotherapy treatment (CLAG
regimen) with Imatinib Mesylate (Gleevec) in patients with AML.